Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda, Merck’s anti-PD-1 therapy, met one… read more.
Skin cancer detection using artificial intelligence (AI) software has rapidly improved, new research has shown, with the latest software reaching a 100% detection rate for melanoma.1 The study,… read more.
The majority of research and public discourse on US maternal mortality focuses on pregnancy-related maternal deaths—deaths caused or accelerated by a pregnancy—rather than the broader category of pregnancy-associated maternal deaths, which… read more.
Arcutis Biotherapeutics, Inc. announced the FDA has approved the supplemental new drug application (sNDA) to expand the indication of Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.
The rapid transition to virtual care that occurred with the onset of the COVID-19 pandemic resulted in better continuity of psychotherapy visits compared to prior to the pandemic… read more.
A new paper in the journal Function, published by Oxford Univetrsity Press, finds that a widely prescribed drug for treating hypertension, amlodipine, is not dangerous for patients, despite recent concerns… read more.
AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie… read more.
Among patients with treatment resistant epilepsy, the investigative drug XEN1101 has reduced seizure frequency by over 50%. And in some patients it stops them completely. Researchers reported these… read more.
A new study may offer a strategy that mitigates negative side effects associated with intravenous injection of nanoparticles commonly used in medicine. The study was published today in Nature… read more.
Neurelis, Inc., announced additional findings from the post hoc analysis of the long-term phase III safety study of Valtoco (diazepam nasal spray) in a pediatric population, aged 6-17… read more.
A comprehensive guideline from Osteoporosis Canada aims to help primary care professionals deliver care to optimize skeletal health and prevent fractures in postmenopausal females and males who are… read more.
Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use. A recent clinical… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
